Cargando…

Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD

BACKGROUND: There is a lack of data comparing azithromycin to alternative antibiotic choices in managing COPD exacerbations, making appropriate antibiotic selection controversial. OBJECTIVE: To compare treatment failure in hospitalized patients with acute exacerbations of chronic obstructive pulmona...

Descripción completa

Detalles Bibliográficos
Autores principales: Baalbaki, Nour, Giuliano, Christopher, Hartner, Carrie L., Kale-Pradhan, Pramodini, Johnson, Leonard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939242/
https://www.ncbi.nlm.nih.gov/pubmed/35316516
http://dx.doi.org/10.1007/s11606-022-07486-5
_version_ 1784672703161040896
author Baalbaki, Nour
Giuliano, Christopher
Hartner, Carrie L.
Kale-Pradhan, Pramodini
Johnson, Leonard
author_facet Baalbaki, Nour
Giuliano, Christopher
Hartner, Carrie L.
Kale-Pradhan, Pramodini
Johnson, Leonard
author_sort Baalbaki, Nour
collection PubMed
description BACKGROUND: There is a lack of data comparing azithromycin to alternative antibiotic choices in managing COPD exacerbations, making appropriate antibiotic selection controversial. OBJECTIVE: To compare treatment failure in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) receiving azithromycin or beta-lactams. DESIGN: Retrospective, multicenter cohort study using logistic regression for multivariable analysis. Patients were included if they were at least 18 years old, admitted with AECOPD, and received at least two consecutive days of either a beta-lactam or azithromycin. Patients were excluded if they received concomitant azithromycin and beta-lactam antibiotics during the first 2 days, had a history of other severe underlying pulmonary diseases, pregnancy, COVID-19, alpha-1 antitrypsin deficiency, or received a corticosteroid for a diagnosis other than COPD. PARTICIPANTS: Five hundred ninety-five patients were included, of which 428 (72%) received azithromycin and 167 patients (28%) received a beta-lactam. MAIN MEASURES: The primary endpoint was treatment failure rate in patients receiving azithromycin versus beta-lactams, which was a composite endpoint defined as in-hospital mortality, admission to intensive care, initiation of invasive mechanical ventilation, initiation of a new antibiotic, steroid therapy escalation, or readmission due to AECOPD within 30 days. KEY RESULTS: The composite primary outcome occurred in 84 patients (19.6%) in the azithromycin group and 54 (32.3%) in the beta-lactam group (p<0.01). The difference in the composite outcome was a result of higher rates of new antibiotics during admission (12.6% vs 4.2%; p<0.01) and higher readmission within 30 days (19.3% vs 12.4%; p=0.032). After controlling for potential confounders, beta-lactams continued to demonstrate a higher risk for treatment failure (OR, 2.30; 95% CI, 1.46–3.63). There was no difference in adverse effects between the groups. CONCLUSION: Azithromycin was associated with less treatment failure in AECOPD which was driven by lower readmission rates and prescription of new antimicrobials.
format Online
Article
Text
id pubmed-8939242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89392422022-03-23 Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD Baalbaki, Nour Giuliano, Christopher Hartner, Carrie L. Kale-Pradhan, Pramodini Johnson, Leonard J Gen Intern Med Original Research BACKGROUND: There is a lack of data comparing azithromycin to alternative antibiotic choices in managing COPD exacerbations, making appropriate antibiotic selection controversial. OBJECTIVE: To compare treatment failure in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) receiving azithromycin or beta-lactams. DESIGN: Retrospective, multicenter cohort study using logistic regression for multivariable analysis. Patients were included if they were at least 18 years old, admitted with AECOPD, and received at least two consecutive days of either a beta-lactam or azithromycin. Patients were excluded if they received concomitant azithromycin and beta-lactam antibiotics during the first 2 days, had a history of other severe underlying pulmonary diseases, pregnancy, COVID-19, alpha-1 antitrypsin deficiency, or received a corticosteroid for a diagnosis other than COPD. PARTICIPANTS: Five hundred ninety-five patients were included, of which 428 (72%) received azithromycin and 167 patients (28%) received a beta-lactam. MAIN MEASURES: The primary endpoint was treatment failure rate in patients receiving azithromycin versus beta-lactams, which was a composite endpoint defined as in-hospital mortality, admission to intensive care, initiation of invasive mechanical ventilation, initiation of a new antibiotic, steroid therapy escalation, or readmission due to AECOPD within 30 days. KEY RESULTS: The composite primary outcome occurred in 84 patients (19.6%) in the azithromycin group and 54 (32.3%) in the beta-lactam group (p<0.01). The difference in the composite outcome was a result of higher rates of new antibiotics during admission (12.6% vs 4.2%; p<0.01) and higher readmission within 30 days (19.3% vs 12.4%; p=0.032). After controlling for potential confounders, beta-lactams continued to demonstrate a higher risk for treatment failure (OR, 2.30; 95% CI, 1.46–3.63). There was no difference in adverse effects between the groups. CONCLUSION: Azithromycin was associated with less treatment failure in AECOPD which was driven by lower readmission rates and prescription of new antimicrobials. Springer International Publishing 2022-03-22 2022-12 /pmc/articles/PMC8939242/ /pubmed/35316516 http://dx.doi.org/10.1007/s11606-022-07486-5 Text en © The Author(s) under exclusive licence to Society of General Internal Medicine 2022
spellingShingle Original Research
Baalbaki, Nour
Giuliano, Christopher
Hartner, Carrie L.
Kale-Pradhan, Pramodini
Johnson, Leonard
Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD
title Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD
title_full Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD
title_fullStr Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD
title_full_unstemmed Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD
title_short Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD
title_sort azithromycin versus beta-lactams in hospitalized patients with acute exacerbations of copd
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939242/
https://www.ncbi.nlm.nih.gov/pubmed/35316516
http://dx.doi.org/10.1007/s11606-022-07486-5
work_keys_str_mv AT baalbakinour azithromycinversusbetalactamsinhospitalizedpatientswithacuteexacerbationsofcopd
AT giulianochristopher azithromycinversusbetalactamsinhospitalizedpatientswithacuteexacerbationsofcopd
AT hartnercarriel azithromycinversusbetalactamsinhospitalizedpatientswithacuteexacerbationsofcopd
AT kalepradhanpramodini azithromycinversusbetalactamsinhospitalizedpatientswithacuteexacerbationsofcopd
AT johnsonleonard azithromycinversusbetalactamsinhospitalizedpatientswithacuteexacerbationsofcopd